KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesChange in Working CapitalExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet Equity Issued and RepurchasedNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Non-cash Items (2017 - 2025)

Historic Non-cash Items for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $3.3 billion.

  • Novartis Ag's Non-cash Items fell 3257.1% to $3.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $11.2 billion, marking a year-over-year decrease of 958.94%. This contributed to the annual value of $11.2 billion for FY2025, which is 974.39% up from last year.
  • Per Novartis Ag's latest filing, its Non-cash Items stood at $3.3 billion for Q4 2025, which was down 3257.1% from $2.3 billion recorded in Q3 2025.
  • Novartis Ag's 5-year Non-cash Items high stood at $5.2 billion for Q4 2023, and its period low was -$11.9 billion during Q4 2021.
  • Over the past 5 years, Novartis Ag's median Non-cash Items value was $2.7 billion (recorded in 2023), while the average stood at $2.2 billion.
  • As far as peak fluctuations go, Novartis Ag's Non-cash Items tumbled by 69794.69% in 2021, and later soared by 12308.01% in 2022.
  • Novartis Ag's Non-cash Items (Quarter) stood at -$11.9 billion in 2021, then surged by 123.08% to $2.8 billion in 2022, then soared by 90.46% to $5.2 billion in 2023, then fell by 6.71% to $4.9 billion in 2024, then tumbled by 32.57% to $3.3 billion in 2025.
  • Its Non-cash Items was $3.3 billion in Q4 2025, compared to $2.3 billion in Q3 2025 and $3.0 billion in Q2 2025.